Literature DB >> 8370724

Cell-free plasma human immunodeficiency virus type 1 titer assessed by culture and immunocapture-reverse transcription-polymerase chain reaction.

R W Coombs1, D R Henrard, W F Mehaffey, J Gibson, E Eggert, T C Quinn, J Phillips.   

Abstract

The relationship between plasma human immunodeficiency virus type 1 (HIV-1) infectious titer, determined by quantitative fivefold end-point dilution culture, and the detection of genomic HIV-1 RNA by immunocapture-cDNA-polymerase chain reaction was determined. The optimal plasma specimen collection and storage conditions for the use of such virologic markers for clinical trials were also determined. The variabilities in the measurement of infectious HIVLAI titer associated with intra- and interdonor peripheral blood mononuclear cells were 1.2 and 0.86 log10 50% tissue culture infective doses (TCID50)/ml (95% confidence interval range), respectively. Plasma HIV-1 titers did not change significantly after storing whole blood for 6 h either at 4 degrees C or ambient temperature or plasma for a median of 267 days (range, 259 to 482) at -70 degrees C. The detection of genomic HIV-1 RNA encapsulated in viral particles was very consistent, reproducible, and unaffected by either heparin or acid citrate or by multiple freeze-thawing. The HIV-1 RNA titers also appeared to generally correlate with the biologic titer obtained by the microculture assay. The consistency in infectious HIV-1 titer was evaluated by using 27 unfrozen plasma specimens collected from five subjects over 1 to 9 days. The median change in HIV-1 titer relative to baseline was -0.5 log10 TCID50/ml (interquartile range, -1.03 to 0.175 log10). In contrast, no significant change in HIV-1 RNA for the same frozen plasma specimens was noted. As such, immunocapture-cDNA-polymerase chain reaction may be a useful measure of plasma viremia for studying the natural history of HIV disease and assessing response to therapy.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8370724      PMCID: PMC265683          DOI: 10.1128/jcm.31.8.1980-1986.1993

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  16 in total

1.  Effects of anticoagulants and storage of blood samples on efficacy of the polymerase chain reaction assay for hepatitis C virus.

Authors:  J T Wang; T H Wang; J C Sheu; S M Lin; J T Lin; D S Chen
Journal:  J Clin Microbiol       Date:  1992-03       Impact factor: 5.948

2.  Stability and inactivation of HTLV-III/LAV under clinical and laboratory environments.

Authors:  L Resnick; K Veren; S Z Salahuddin; S Tondreau; P D Markham
Journal:  JAMA       Date:  1986-04-11       Impact factor: 56.272

3.  Detection and quantification of human immunodeficiency virus RNA in patient serum by use of the polymerase chain reaction.

Authors:  M Holodniy; D A Katzenstein; S Sengupta; A M Wang; C Casipit; D H Schwartz; M Konrad; E Groves; T C Merigan
Journal:  J Infect Dis       Date:  1991-04       Impact factor: 5.226

4.  Dissociation of gp120 from HIV-1 virions induced by soluble CD4.

Authors:  J P Moore; J A McKeating; R A Weiss; Q J Sattentau
Journal:  Science       Date:  1990-11-23       Impact factor: 47.728

5.  Quantitation of human immunodeficiency virus type 1 in the blood of infected persons.

Authors:  D D Ho; T Moudgil; M Alam
Journal:  N Engl J Med       Date:  1989-12-14       Impact factor: 91.245

6.  Efficient isolation of HIV from plasma during different stages of HIV infection.

Authors:  A Ehrnst; A Sönnerborg; S Bergdahl; O Strannegård
Journal:  J Med Virol       Date:  1988-09       Impact factor: 2.327

7.  High-level viremia in adults and children infected with human immunodeficiency virus: relation to disease stage and CD4+ lymphocyte levels.

Authors:  M S Saag; M J Crain; W D Decker; S Campbell-Hill; S Robinson; W E Brown; M Leuther; R J Whitley; B H Hahn; G M Shaw
Journal:  J Infect Dis       Date:  1991-07       Impact factor: 5.226

8.  Plasma viremia in human immunodeficiency virus infection.

Authors:  R W Coombs; A C Collier; J P Allain; B Nikora; M Leuther; G F Gjerset; L Corey
Journal:  N Engl J Med       Date:  1989-12-14       Impact factor: 91.245

9.  Isolation of human immunodeficiency virus (HIV) from plasma during primary HIV infection.

Authors:  J Albert; H Gaines; A Sönnerborg; G Nyström; P O Pehrson; F Chiodi; M von Sydow; L Moberg; K Lidman; B Christensson
Journal:  J Med Virol       Date:  1987-09       Impact factor: 2.327

10.  Infectious decay of human immunodeficiency virus type 1 in plasma.

Authors:  T Moudgil; E S Daar
Journal:  J Infect Dis       Date:  1993-01       Impact factor: 5.226

View more
  18 in total

1.  Intra- and interlaboratory variabilities of results obtained with the Quantiplex human immunodeficiency virus type 1 RNA bDNA assay, version 3.0.

Authors:  J A Kellogg; P V Atria; J C Sanders; M E Eyster
Journal:  Clin Diagn Lab Immunol       Date:  2001-05

2.  Evaluation of an infectivity standard for real-time quality control of human immunodeficiency virus type 1 quantitative micrococulture assays. Participating Laboratories of The AIDS Clinical Trials Group.

Authors:  W A Scott; D Brambilla; E Siwak; C Beatty; J Bremer; R W Coombs; H Farzadegan; S A Fiscus; S M Hammer; F B Hollinger; N Khan; S Rasheed; P S Reichelderfer
Journal:  J Clin Microbiol       Date:  1996-09       Impact factor: 5.948

3.  Stability of human immunodeficiency virus RNA in blood specimens as measured by a commercial PCR-based assay.

Authors:  K Sebire; K McGavin; S Land; T Middleton; C Birch
Journal:  J Clin Microbiol       Date:  1998-02       Impact factor: 5.948

4.  TaqMan real-time reverse transcription-PCR and JDVp26 antigen capture enzyme-linked immunosorbent assay to quantify Jembrana disease virus load during the acute phase of in vivo infection.

Authors:  Meredith Stewart; Moira Desport; Nining Hartaningsih; Graham Wilcox
Journal:  J Clin Microbiol       Date:  2005-11       Impact factor: 5.948

Review 5.  Use of virologic assays for detection of human immunodeficiency virus in clinical trials: recommendations of the AIDS Clinical Trials Group Virology Committee.

Authors:  S Hammer; C Crumpacker; R D'Aquila; B Jackson; J Lathey; D Livnat; P Reichelderfer
Journal:  J Clin Microbiol       Date:  1993-10       Impact factor: 5.948

6.  Optimization of quantitative culture assay for human immunodeficiency virus from plasma. Plasma Viremia Group Laboratories of the AIDS Clinical Trials Group (National Institute of Allergy and Infectious Diseases).

Authors:  J L Lathey; S A Fiscus; S Rasheed; J C Kappes; B P Griffith; T Elbeik; S A Spector; P S Reichelderfer
Journal:  J Clin Microbiol       Date:  1994-12       Impact factor: 5.948

7.  Effects of anticoagulant, processing delay, and assay method (branched DNA versus reverse transcriptase PCR) on measurement of human immunodeficiency virus type 1 RNA levels in plasma.

Authors:  L M Kirstein; J W Mellors; C R Rinaldo; J B Margolick; J V Giorgi; J P Phair; E Dietz; P Gupta; C H Sherlock; R Hogg; J S Montaner; A Muñoz
Journal:  J Clin Microbiol       Date:  1999-08       Impact factor: 5.948

8.  Development of calibrated viral load standards for group M subtypes of human immunodeficiency virus type 1 and performance of an improved AMPLICOR HIV-1 MONITOR test with isolates of diverse subtypes.

Authors:  N L Michael; S A Herman; S Kwok; K Dreyer; J Wang; C Christopherson; J P Spadoro; K K Young; V Polonis; F E McCutchan; J Carr; J R Mascola; L L Jagodzinski; M L Robb
Journal:  J Clin Microbiol       Date:  1999-08       Impact factor: 5.948

9.  Detection of p24 antigen with and without immune complex dissociation for longitudinal monitoring of human immunodeficiency virus type 1 infection.

Authors:  D R Henrard; S Wu; J Phillips; D Wiesner; J Phair
Journal:  J Clin Microbiol       Date:  1995-01       Impact factor: 5.948

10.  A Brief Chronicle of CD4 as a Biomarker for HIV/AIDS: A Tribute to the Memory of John L. Fahey.

Authors:  Jonathan M Kagan; Ana M Sanchez; Alan Landay; Thomas N Denny
Journal:  For Immunopathol Dis Therap       Date:  2015
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.